Reaction: Nelarabine to 1 product

Reaction
Nelarabine
DB01280
9-β-D-arabinofuranosylguanine
DBMET00412
Reaction type
O-demethylation
Direction
Not Available
Major circulating metabolite?
No
Spontaneous?
No
Activity
unknown
References
  1. Robak T, Korycka A, Lech-Maranda E, Robak P: Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules. 2009 Mar 23;14(3):1183-226. doi: 10.3390/molecules14031183. [Article]
  2. Roecker AM, Stockert A, Kisor DF: Nelarabine in the treatment of refractory T-cell malignancies. Clin Med Insights Oncol. 2010 Dec 1;4:133-41. doi: 10.4137/CMO.S4364. [Article]
  3. Muniz-Miranda F, Pedone A, Muniz-Miranda M: Raman and Computational Study on the Adsorption of Xanthine on Silver Nanocolloids. ACS Omega. 2018 Oct 18;3(10):13530-13537. doi: 10.1021/acsomega.8b02174. eCollection 2018 Oct 31. [Article]
  4. Jung H, Hawkins M, Lee S: Structural insights into the bypass of the major deaminated purines by translesion synthesis DNA polymerase. Biochem J. 2020 Dec;477(24):4797-4810. doi: 10.1042/BCJ20200800. Epub 2020 Dec 24. [Article]
  5. Chen C, Lu JM, Yao Q: Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview. Med Sci Monit. 2016 Jul 17;22:2501-12. doi: 10.12659/msm.899852. [Article]
  6. Simoyi MF, Falkenstein E, Van Dyke K, Blemings KP, Klandorf H: Allantoin, the oxidation product of uric acid is present in chicken and turkey plasma. Comp Biochem Physiol B Biochem Mol Biol. 2003 Jun;135(2):325-35. doi: 10.1016/s1096-4959(03)00086-1. [Article]
  7. FDA Approved Drug Products: ARRANON (nelarabine) injection, for intravenous use 2 [Link]
  8. FDA Approved Drug Products: ARRANON® (nelarabine) Injection FOR INTRAVENOUS USE [Link]
Comments
Not Available
Enzymes
EnzymeKmVmaxRole
Adenosine deaminaseNot AvailableNot Availableimplied